Mineralys Therapeutics stock
MLYSNASDAQMineralys Therapeutics, Inc., HealthcareISIN US6031701013
29Score 29 out of 100, Weak
Price and trend
28 / 100
Price history
−67% in one yearThe chart shows daily closes over 4 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 41% below it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 29).
The price is 67% below its 52-week high. Largest decline in 4 years: 69% (March 2023 to November 2023).
Chart figures for advanced users
- SMA 50$22.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.24
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)29
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$15.24
- The lowest closing price of the last twelve months.
- Resistance$47.33
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Mineralys Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.37B, is number 159 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 29 out of 100 (Weak): rank 684 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $656.64M, financial debt $0.Stability 69
Weaknesses
- Share price fell sharplyDown 67% over the last 12 months.Momentum 12
- Loss-makingLoss of $154.65M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$142.43M over the last 12 months.Fundamentals 17
The score is held back by profitability and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 11 Mar 2027in 118 days
- Last reported
- 4 Nov 2026EPS reported −$0.64 (expected −$0.55)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 8.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$4.60−2.6%
- Revenue
- $557.14K0.0%
- Earnings per share
- −$2.59−8.2%
- Revenue
- $78.28M−10.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −1.2%No financial guidance: FDA decision date expected in December, the sales organization is expected to be staffed in advance.
“And perhaps most importantly, expect our sales organization to be staffed in advance of our December PDUFA target date.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $11.89M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Congleton JonSale
30 Sept 2026, Chief Executive Officer
- Shares
- 75,000
- Price
- $25.46
- Value
- $1.91M
- Slingsby Brian TaylorSale
22 Sept 2026, Board
- Shares
- 104,320
- Price
- $28.81
- Value
- $3.01M
- Warren EricSale
21 Sept 2026, Chief Commercial Officer
- Shares
- 7,438
- Price
- $28.12
- Value
- $209,136
Show 17 more
- Karydas DaphneSale
15 Sept 2026, Board
- Shares
- 3,000
- Price
- $28.58
- Value
- $85,740
- Warren EricSale
21 Aug 2026, Chief Commercial Officer
- Shares
- 7,437
- Price
- $25.98
- Value
- $193,189
- Rodman David MalcomSale
10 Aug 2026, Chief Medical Officer
- Shares
- 2,170
- Price
- $27.09
- Value
- $58,785
- Warren EricSale
21 Jul 2026, Chief Commercial Officer
- Shares
- 7,438
- Price
- $26.87
- Value
- $199,885
- Rodman David MalcomSale
17 Jul 2026, Chief Medical Officer
- Shares
- 416
- Price
- $26.53
- Value
- $11,036
- Rodman David MalcomSale
15 Jul 2026, Chief Medical Officer
- Shares
- 6,349
- Price
- $26.61
- Value
- $168,955
- Congleton JonSale
13 Jul 2026, Chief Executive Officer
- Shares
- 10,700
- Price
- $27.24
- Value
- $291,441
- Rodman David MalcomSale
13 Jul 2026, Chief Medical Officer
- Shares
- 14,058
- Price
- $27.58
- Value
- $387,717
- Rodman David MalcomSale
9 Jul 2026, Chief Medical Officer
- Shares
- 2,171
- Price
- $30.30
- Value
- $65,781
- Congleton JonSale
30 Jun 2026, Chief Executive Officer
- Shares
- 75,000
- Price
- $26.14
- Value
- $1.96M
- Warren EricSale
26 Jun 2026, Chief Commercial Officer
- Shares
- 104,124
- Price
- $25.90
- Value
- $2.7M
- Rodman David MalcomSale
17 Jun 2026, Chief Medical Officer
- Shares
- 4,584
- Price
- $25.00
- Value
- $114,600
- Karydas DaphneSale
17 Jun 2026, Board
- Shares
- 3,000
- Price
- $25.00
- Value
- $75,000
- Rodman David MalcomSale
15 Jun 2026, Chief Medical Officer
- Shares
- 9,890
- Price
- $23.81
- Value
- $235,487
- Rodman David MalcomSale
12 Jun 2026, Chief Medical Officer
- Shares
- 6,349
- Price
- $23.93
- Value
- $151,901
- Rodman David MalcomSale
10 Jun 2026, Chief Medical Officer
- Shares
- 2,170
- Price
- $25.00
- Value
- $54,250
- Rodman David MalcomSale
18 May 2026, Chief Medical Officer
- Shares
- 417
- Price
- $27.55
- Value
- $11,488
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Mineralys Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 29
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Alto NeuroscienceANRO $1.42B41
- Ascentage Pharma Group InternationalAAPG $1.4B37
- Ocular TherapeutixOCUL $1.38B34
- LB PharmaceuticalsLBRX $1.37B49
- Damora TherapeuticsDMRA $1.36B38
- Tyra BiosciencesTYRA $1.36B36
- Avalyn PharmaAVLN $1.36B41
- InnovivaINVA $1.35B67
ETFs that hold Mineralys Therapeutics
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €964.08M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.